Advancing Investigational
Photo Neuromodulation for Parkinson’s Disease
Celeste® is an investigational device being studied to better understand the role of retinal and circadian signaling pathways in Parkinson’s disease.
Addressing Major Unmet Needs
in Parkinson’s Disease
Parkinson’s disease affects more than 11 million people worldwide, a number expected to grow significantly in the coming decades. While advances in symptom management have helped many people live longer and more active lives, substantial unmet needs remain.
Many individuals living with Parkinson’s disease experience challenges that extend beyond movement, including sleep disturbances, fatigue, mood changes, cognitive difficulties, and disruptions to daily life. These symptoms can significantly impact independence, wellbeing, and overall quality of life.
PhotoPharmics was founded to explore whether targeted light-based interventions may influence biological pathways involved in neurological function. The company’s research focuses on the relationship between light-responsive retinal pathways, circadian biology, and the brain.
Celeste® is an investigational photo-neuromodulation device being evaluated for Parkinson’s disease. Through a series of clinical studies, PhotoPharmics has explored the potential role of this approach in addressing important unmet needs within the Parkinson’s community.
We are grateful to the participants, caregivers, investigators, researchers, and advocates who have contributed to this work and invite you to follow our ongoing scientific and regulatory journey.
Sign Up for Updates
Seeing Photo-Neuromodulation Clearly
Celeste® is an investigational photo-neuromodulation device being evaluated for Parkinson’s disease.
SCIENCE-BASED
Built upon research exploring how light-responsive retinal pathways communicate with broader neurological systems.
NON-INVASIVE
Designed to deliver light through the eyes
without surgery or implanted hardware.
HOME-BASED
Developed for use in a familiar home environment
as part of ongoing clinical research.
LATEST UPDATES
The Role of Nutrition in Parkinson’s Disease
Introduction Did you know that unintentional weight loss and nutritional deficiencies are among the most common challenges for people with Parkinson’s disease, often occurring even before a diagnosis is made? In simple terms, Parkinson’s Disease is a condition where...
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics, a clinical-stage medical device company pioneering Photo Neuromodulation for neurodegenerative disease, today announced it has surpassed its enrollment target with 350 participants in its pivotal, Phase 3 Light for PD clinical trial evaluating the...
Young-Onset Parkinson’s: Navigating Your Journey After an Early Diagnosis
Introduction Receiving a Parkinson's disease diagnosis is a life-altering moment. When that moment comes decades earlier than expected—sometime between the ages of 21 and 50—it brings a unique set of questions, challenges, and emotions. A Young-Onset Parkinson's...
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in Parkinson’s care PhotoPharmics, a clinical-stage medtech device company specializing in non-invasive photo neurostimulation, today announced its participation in the 2025...
Understanding and Managing Depression and Anxiety in Parkinson’s
Introduction Did you know that at least 50% of people with Parkinson's Disease (PD) will experience some form of depression during their illness, and up to 40% will face a significant anxiety disorder? If you've been grappling with your mood, you are far from alone....